{"product_id":"landmark-studies-in-critical-care-the-evidence-base-of-contemporary-practice-9789819506729","title":"Landmark Studies in Critical Care: The Evidence Base of Contemporary Practice","description":"\u003cp\u003e • Author(s): Jose Chacko | Donald B. Chalfin | Ian Seppelt\u003cbr\u003e • Publisher: Springer\u003cbr\u003e • Publisher Imprint: Springer\u003cbr\u003e • BISAC: Critical Care\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart I: Mechanical Ventilation and Respiratory Failure\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 1. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eNeuromuscular Blockers in Acute Respiratory Distress Syndrome: The ACURASYS Trial.-2. Ventilation with Low Tidal Volumes in Acute Respiratory Distress Syndrome: The ARDS-Net Trial.- 3. Prone Ventilation in Severe Acute Respiratory Distress Syndrome: The PROSEVA Trial.- 4. Timing of Tracheostomy: Early vs. Late Tracheostomy in Mechanically Ventilated Patients: The TRACMAN Trial.- 5. High-Frequency Oscillation in Acute Respiratory Distress Syndrome: The OSCILLATE Trial.- 6. High-Frequency Oscillation in Acute Respiratory Distress Syndrome: The OSCAR Trial.- 7. Positive End-Expiratory Pressure Setting in Acute Respiratory Distress Syndrome: The EXPRESS Trial.- 8. Comparison of Different Methods of Weaning from Mechanical Ventilation: Esteban et al.- 9. Noninvasive Ventilation for Chronic Obstructive Pulmonary Disease: Brochard et al.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart II: Fluid Management\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e10. Albumin vs. Normal Saline for Resuscitation: The SAFE Trial.- 11. Albumin Replacement in Severe Sepsis and Septic Shock: The ALBIOS Trial.- 12. Hydroxyethyl Starch vs. Normal Saline for Fluid Resuscitation: The CHEST Trial.- 13. Balanced Crystalloid vs. Normal Saline for Resuscitation: The SMART Trial.- 14. Balanced Crystalloid vs. Normal Saline for Resuscitation: The BaSICS Trial.- 15. Balanced Multielectrolyte Solution vs. Normal Saline for Resuscitation: The PLUS Trial.- 16. Conservative vs. Liberal Fluid Management in ARDS: The FACTT Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart III: Cardiopulmonary Resuscitation\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 17. Compression-Only Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest: The DART Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart IV: Neurosciences\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 18. Intracranial Pressure Monitoring and Outcomes in Traumatic Brain Injury: The BEST-TRIP Trial.- 19. Methylprednisolone in Severe Traumatic Brain Injury: The CRASH Trial.- 20. Thrombectomy at 6 to 24 Hours Following Stroke with Mismatch Between Deficit and Infarct Size\u003cspan style=\"color: black; mso-themecolor: text1;\"\u003e: The DAWN Trial.- 21. Decompressive Craniectomy in Severe Diffuse Traumatic Brain Injury: The DECRA Trial.- 22. Decompressive Craniectomy for Intracranial Hypertension Following Traumatic Brain Injury: The RESCUEicp Trial.- 23. Decompressive Craniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke: The DESTINY II Trial.- 24. Intravenous Thrombolysis Between 3–4.5 Hours After Stroke: The ECASS 3 Trial.- 25. A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus: Treiman et al.- 26. Neurosurgical Clipping vs. Endovascular Coiling in Ruptured Intracranial Aneurysms: The ISAT Trial.- 27. Tissue Plasminogen Activator for Acute Ischemic Stroke: The NINDS Trial.- 28. Tranexamic Acid in Traumatic Brain Injury: The CRASH-3 Trial.- \u003c\/span\u003e\u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart V: Corticosteroids in Sepsis\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: black; mso-themecolor: text1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 29. Hydrocortisone-Fludrocortisone Combination in Septic Shock: Annane et al.- 30. Hydrocortisone in Septic Shock: The CORTICUS Trial.- 31. Hydrocortisone in Septic Shock: The ADRENAL Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart VI: Corticosteroids in ARDS\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: black; mso-themecolor: text1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 32. Methylprednisolone for Unresolving Acute Respiratory Distress Syndrome: Meduri et al.- 33. Corticosteroids in Persistent Acute Respiratory Distress Syndrome: The LAsRS Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart VII: Nephrology and Renal Replacement Therapy\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: black; mso-themecolor: text1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 34. Low-Dose Dopamine in Early Renal Dysfunction: The ANZICS Dopamine Trial.- 35. Continuous Venovenous Hemodiafiltration vs. Intermittent Hemodialysis for Acute Kidney Injury in the Critically Ill: The HEMODIAFE Trial.- 36. Timing of Renal Replacement Therapy in Critically Ill Patients with Acute Kidney Injury: The AKIKI Trial.- 37. Comparing Two Delayed Strategies for Renal Replacement Therapy Initiation in Severe Acute Kidney Injury: The AKIKI 2 Trial.- 38. Early vs. Late Initiation of Renal Replacement Therapy in Acute Kidney Injury: The ELAIN Trial.- 39. Timing of Renal Replacement Therapy in Septic Shock with Acute Kidney Injury: The IDEAL-ICU Trial.- 40. Timing of Initiation of Renal Replacement Therapy in Acute Kidney Injury: The STARRT-AKI Trial.- 41. Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury: The VA\/NIH Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart VIII: Trauma\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: black; mso-themecolor: text1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 42. Immediate vs. Delayed Resuscitation in Penetrating Torso Injury: Bickell et al.- 43. Tranexamic Acid in Bleeding Trauma Patients: The CRASH-2 Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart IX: Extracorporeal Support\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: black; mso-themecolor: text1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 44. Extracorporeal Membrane Oxygenation in Acute Respiratory Failure: The CESAR Trial.- 45. Extracorporeal Membrane Oxygenation in Severe Acute Respiratory Distress Syndrome: The EOLIA Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart X: Infections\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 46. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eDuration of Antibiotic Therapy for Ventilator-Associated Pneumonia: The PNEUMA Trial.- 47. Duration of Hypotension Before Effective Antibiotic Therapy and Survival in Septic Shock: Kumar et al.- 48. Diagnostic Techniques for Ventilator-Associated Pneumonia: Canadian Critical Care Trials Group.- 49. Procalcitonin and Antibiotic Exposure in the ICU: The PRORATA Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XI: Cardiology, Cardiac Surgery\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 50. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eRate vs. Rhythm Control for Atrial Fibrillation Following Post-Cardiac Surgery: The CTSN Trial.- 51. Optimal PCI Strategy in Cardiogenic Shock Following Acute Myocardial Infarction: The CULPRIT-SHOCK Trial.- 52. \u003cspan style=\"color: black; mso-themecolor: text1;\"\u003eCoronary Angioplasty vs. Fibrinolytic Therapy in Acute Myocardial Infarction: The DANAMI-2 Trial.- \u003cstrong\u003e\u003cspan style=\"font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;\"\u003ePart \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eXII: Sepsis – Resuscitation\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 53. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eGoal-Directed Resuscitation in Sepsis:\u003cspan style=\"mso-spacerun: yes;\"\u003e  \u003c\/span\u003eThe Rivers et al., ProCESS, ARISE, and ProMISe Trials\u003cspan style=\"color: black; mso-themecolor: text1;\"\u003e.- 54. Dopamine vs. Norepinephrine in the Treatment of Shock: The SOAP II Trial.- 55. Vasopressin vs. Norepinephrine in Septic Shock: The VAAST Trial.- \u003c\/span\u003e\u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XIII: Nutrition\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; color: black; mso-themecolor: text1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 56. Early versus Late Parenteral Nutrition in the Critically Ill: The EPANIC Trial.- 57. Initial Trophic vs. Full Enteral Feeding in Acute Lung Injury: The EDEN Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XIV: Therapeutic Hypothermia\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 58. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eTherapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: The HACA Trial.- 59. Targeted Temperature Management After Cardiac Arrest: 33°C vs. 36°C: The TTM Trial\u003cspan style=\"color: black; mso-themecolor: text1;\"\u003e.- 60. Hypothermia or Normothermia After Out-of-Hospital Cardiac Arrest? The TTM 2 Trial.- \u003c\/span\u003e\u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XV: Sedation in the ICU\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 61. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eDaily Interruption of Sedation in Mechanically Ventilated Patients: Kress et al.- 62. A Combined Sedation and Ventilator Weaning Protocol for Mechanically Ventilated Patients: The ABC Trial.- 63. No Sedation vs. Light Sedation in Mechanically Ventilated Patients: The NONSEDA Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XVI: Pulmonary Embolism\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 64. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eThrombolysis for Moderate Pulmonary Embolism: The MOPETT Trial.- 65. Fibrinolysis in Intermediate-Risk Pulmonary Embolism: The PEITHO Trial.- 66. Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs. Anticoagulation Alone and Recurrent Pulmonary Embolism: The PREPIC2 Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XVII: Glucose Control\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 67. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eIntensive vs. Conventional Glucose Control in the ICU: The NICE-SUGAR Trial.- 68. Intensive Insulin Therapy in the Surgical ICU: The Leuven 1 Trial.- 69. Intensive Insulin Therapy in the Medical ICU: The Leuven 2 Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XVIII: Transfusion Thresholds\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 70. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eTransfusion Thresholds in the Critically Ill: The TRICC Trial.- 71. Transfusion Thresholds in Septic Shock: The TRISS Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XIX: Covid-19 Pneumonia\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 72. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eRemdesivir for COVID-19 Pneumonia: The ACTT-1 Trial.- 73. Dexamethasone in COVID-19 Infection: The RECOVERY Trial.- \u003c\/span\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-IN; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003ePart XX: Miscellaneous\u003c\/span\u003e\u003c\/strong\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003e.- 74. Acetaminophen for Fever in the Critically Ill: The HEAT Trial.- 75. Step-Up Approach vs. Open Necrosectomy for Acute Necrotizing Pancreatitis: The PANTER Trial.- 76. Intra-aortic Balloon Counterpulsation in Cardiogenic Shock Following Acute Myocardial Infarction: The IABP-SHOCK II Trial.- 77. Pulmonary Artery Catheter in the ICU: The PAC-Man Trial.- 78. Pharmacist Participation on ICU Rounds and Adverse Drug Events: Leape et al.\u003c\/span\u003e\u003c\/p\u003e","brand":"Springer","offers":[{"title":"Hardcover","offer_id":47594512908439,"sku":"9789819506729","price":11208.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0666\/3471\/1191\/files\/9789819506729.webp?v=1774986233","url":"https:\/\/atlanticbooks.com\/products\/landmark-studies-in-critical-care-the-evidence-base-of-contemporary-practice-9789819506729","provider":"Atlantic Books","version":"1.0","type":"link"}